| 引用本文: | 刘晓燕,曾飘容,李君君.慢性髓系白血病无治疗缓解的研究进展[J].中国现代应用药学,2020,37(10):1276-1280. |
| LIU Xiaoyan,ZENG Piaorong,LI Junjun.Advances in Research on Treatment-free Remission of Chronic Myeloid Leukemia[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(10):1276-1280. |
|
| 摘要: |
| 随着酪氨酸激酶抑制剂的引入，慢性髓系白血病的治疗取得了前所未有的进展，大大提高了患者的生存及预后。国内外临床试验表明，部分获得深度分子学反应的慢性髓系白血病患者在数年后可以成功停药，并维持无治疗缓解。本文主要通过总结酪氨酸激酶抑制剂治疗慢性髓系白血病患者获得深度分子学缓解后停药的临床试验，对如何把握安全停药，达到无治疗缓解作一综述。 |
| 关键词: 慢性髓系白血病 酪氨酸激酶抑制剂 停药 无治疗缓解 |
| DOI：10.13748/j.cnki.issn1007-7693.2020.10.023 |
| 分类号:R967 |
| 基金项目: |
|
| Advances in Research on Treatment-free Remission of Chronic Myeloid Leukemia |
|
LIU Xiaoyan, ZENG Piaorong, LI Junjun
|
|
The First Affiliated Hospital of University of South China, Hengyang 421001, China
|
| Abstract: |
| With the introduction of tyrosine kinase inhibitor(TKI), the treatment of chronic myeloid leukemia(CML) has made unprecedented breakthroughs, greatly improving the survival and prognosis of patients with CML. Many clinical trials currently have shown that some patients with CML, after receiving TKI treatment and maintaining a deep molecular response, can be successfully discontinued after several years. This article mainly summarizes the clinical trials of TKI in the treatment of CML patients who stop taking drugs after after receiving deep molecular remission, and how to grasp safe withdrawal and achieve treatment-free remission. |
| Key words: chronic myeloid leukemia tyrosine kinase inhibitor withdrawal treatment-free remission |
